18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)
about
Rapid development of image analysis research tools: Bridging the gap between researcher and clinician with pyOsiriX.Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiologyRadium-223 dichloride in clinical practice: a review.Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.Factors Affecting Uptake of NaF-18 by the Normal Skeleton.Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.Comparison of standardized uptake values measured on F-NaF PET/CT scans using three different tube current intensitiesCastration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.Functional imaging for prostate cancer: therapeutic implications.Molecular imaging of prostate cancer: PET radiotracers.Receiver operating characteristic (ROC) curve for classification of (18)F-NaF uptake on PET/CT.Longitudinal analysis of bone metabolism using SPECT/CT and (99m)Tc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis.Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.Bone-Targeted Imaging and Radionuclide Therapy in Prostate CancerTargeted α-particle therapy of bone metastases in prostate cancerMolecular imaging of urogenital diseases.Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.Therapy assessment of bone metastatic disease in the era of 223radium.Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.(18)F-NaF PET/CT: EANM procedure guidelines for bone imaging.Novel three-dimensional bone 'mapping' software can help assess progression of osseous metastases from routine CT.Radium-223 IN metastatic hormone-sensitive high-grade prostate cancer: initial experience.The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer
P2860
Q27317305-38E0BAF4-7CD0-4602-AA22-414C5EB93CEEQ28071705-0D911656-4763-4974-A1BD-A3804264EBBCQ30251496-FD17B611-064E-476F-880F-344DFEEFC56EQ33625371-72EE6D09-72B9-4569-8E94-E92C75BCFB06Q34213019-92590B44-A192-482F-8B57-C7BC6A8B5AB6Q34642993-95B1F079-5D9F-4740-8F8C-49F7B7C9C01CQ35195454-BAC9F1C0-1824-4D77-A62B-AD1C6111B1FCQ35541792-B34C1F91-F3D9-4AF9-A7AD-B589D5020A1CQ36128629-7FBC9091-EE0E-4A99-958F-5598FA5160E0Q36129937-6F667CD5-BD79-41C6-A46C-F799C601A3AFQ36628451-29C9114D-1905-4B6E-B03F-BEEBEB69FF82Q37131629-45D8D648-30FF-4474-85DB-1B03FA8CD2B4Q37261280-ABEEA22F-D96E-4AE1-8B0C-31FE9492F3B5Q37390666-00D7DE29-1B60-427C-965D-225359326DB9Q37417656-88D9F769-E3E6-4745-9F2D-07E2B1E6E9A1Q37550399-ECF3C5EC-17AB-47E1-95E2-081F1F1E73B7Q38306050-63BEE11B-5427-4000-9595-17E4EBE9B5F6Q39001530-83BA3D97-E1DA-45D2-9856-136330A647DBQ39342954-32109643-3139-432B-BF7F-548C7DD0A5EEQ39607583-710871BA-ABC7-4093-B2E3-4EFB911C8A4BQ40215364-1FBE3DD9-5E89-4661-8B46-B2D647BC4BEEQ40707077-ED350447-A7B1-400B-AA3F-EA7281F33DE7Q41571782-69B59C1D-9C7F-4159-B0A8-A392572B794EQ47146368-EAE8D135-FE4B-46C8-9C1C-9359A88DFA96Q48282284-A0F8C288-5BD2-402C-BEAF-258F8F28C98CQ49874595-0A3B94C1-A7A3-4613-9C30-0DDD1ECD222FQ57118441-E58603E1-09F8-4179-816D-03849339CC84
P2860
18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
18F-fluoride PET: changes in u ...... th 223Ra-chloride (Alpharadin)
@ast
18F-fluoride PET: changes in u ...... th 223Ra-chloride (Alpharadin)
@en
type
label
18F-fluoride PET: changes in u ...... th 223Ra-chloride (Alpharadin)
@ast
18F-fluoride PET: changes in u ...... th 223Ra-chloride (Alpharadin)
@en
prefLabel
18F-fluoride PET: changes in u ...... th 223Ra-chloride (Alpharadin)
@ast
18F-fluoride PET: changes in u ...... th 223Ra-chloride (Alpharadin)
@en
P2093
P2860
P356
P1433
P1476
18F-fluoride PET: changes in u ...... th 223Ra-chloride (Alpharadin)
@en
P2093
Anne-Kirsti Aksnes
Bernadette Johnson
Chris Parker
P2860
P2888
P356
10.1186/2191-219X-1-4
P577
2011-06-07T00:00:00Z
P6179
1035541884